Under the terms of the agreement, Algaeon will develop manufacturing and technology processes while Valensa will produce finished form, condition-specific products that will be sold to marketers with recognized brands.
Valensa’s ingredient and formulation portfolio already includes such algae-based products as Zanthin brand Astaxanthin, Parry Organic Spirulina, SpiruZan (astaxanthin + spirulina) tablets and phycocyanin-coated Pur-Blue SpiruZan.
According to Valensa president and CEO Dr. Rudi E. Moerck, the algae technology relationship with Algaeon provides a significant additional supplier of algae biomass and extracts to Valensa to allow the company to grow its portfolio of advanced condition-specific products.
“Valensa is a rapidly growing nutraceutical company with a thriving astaxanthin-based, condition-specific formulation business,” said Moerck in a statement. “We are excited and confident that this collaboration with Algaeon will provide additional algae-sourced ingredients to Valensa to ultimately expand its offerings beyond Spirulina and Astaxanthin.”